EN DE

BioRem Inc (BRM) Fair Value & Analysis

Industrials · CA · Market cap C$50.0M

BI BioRem Inc BRM · V
PriceC$3.77
Fair ValueC$5.53
Upside+46.7%
Quality73/100
Watch BioRem Inc for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Solidly profitable · 11.2% net margin
Low debt · generates free cash flow
Ranks above peers (10/13)
Moderate moat 64/100
Evidence: High Range C$4.11 – C$6.94 Share as image

Fair value as of: Jul 15, 2026

From 26 valuation models · updated 27 days ago

Share price +24.4% over the past month.

A solid business, screening 47% undervalued on our models.

What matters now

  • The rarer combination: high quality (73/100) AND below fair value. That earns a closer look rather than a quick verdict.
  • The price is below even our cautious bear case (C$4.11). The market is more pessimistic than our downside scenario.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

C$3.77 C$0.4300 Fair Value C$5.53 Apr 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.

How to read this chart

60‑month range C$0.4300 – C$3.77 · fair‑value band C$4.11 – C$6.94 · the C$3.77 price screens below the C$5.53 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 15, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

BioRem Inc (BRM) currently trades at C$3.77, while our model-based Fair Value estimate is C$5.53, implying the stock looks roughly 46.7% undervalued today. The Quality Score stands at 73/100 (solid quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, BioRem Inc generated revenue of C$44.4M at a net margin of 11.2%. Revenue grew 44.1% year over year. It earns a return on equity of 38.3%. Net debt stands at C$1.9M. Fundamentals as of Jul 15, 2026

Our scenario range runs from C$4.11 (bear case) to C$6.94 (bull case); at C$3.77, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 102% above its 52-week low, currently above its 200-day average. For context, the median of 10 Industrials peers we cover trades at -46% fair-value upside, at 47%, BRM screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF C$5.60 C$8.66 C$13.43 80
Residual Income C$1.40 C$1.69 C$4.26 76
Rev-Margin DCF C$5.20 C$8.41 C$15.15 74
All 26 models by family
DCF Models
FCF DCF C$5.94 C$8.07 C$14.29 38
Owner Earnings C$4.00 C$7.25 C$12.93 31
5Y Revenue Exit C$4.79 C$7.43 C$12.93 39
5Y EBITDA Exit C$5.25 C$8.36 C$14.43 41
5Y P/E Exit C$5.53 C$10.93 C$18.17 38
10Y Revenue Exit C$5.10 C$9.38 C$11.83 36
10Y EBITDA Exit C$5.49 C$10.23 C$18.12 37
10Y P/E Exit C$5.67 C$10.75 C$18.83 35
Earnings-Based
Graham-Dodd C$2.02 C$14.07 C$19.74 54
Lynch FV C$7.27 C$10.38 C$13.50 50
PEG = 1.0 C$7.27 C$10.38 C$13.50 46
EPV C$3.23 C$3.55 C$3.80 59
Dividend Discount
Gordon GGM C$2.19 C$3.66 C$4.75 70
DDM Multi-Stage C$2.19 C$3.47 C$3.94 61
Multiples
P/E Multiple C$4.67 C$6.23 C$7.79 63
P/S Multiple C$3.78 C$5.04 C$6.30 58
P/B Multiple C$3.10 C$4.14 C$5.17 55
EV/EBIT C$5.79 C$7.52 C$9.24 53
EV/EBITDA C$4.86 C$6.27 C$7.68 54
EV/Revenue C$3.92 C$5.33 C$6.74 43
Asset-Based
NCAV (Graham) C$0.4600 C$0.6200 C$0.9200 50
Growth DCF
Growth DCF C$5.60 C$8.66 C$13.43 80
Rev-Margin DCF C$5.20 C$8.41 C$15.15 74
Economic Profit
Residual Income C$1.40 C$1.69 C$4.26 76
ROIC Compounder C$3.49 C$4.16 C$4.85 72
Growth Earnings
Growth-Adj P/E C$9.51 C$13.58 C$17.66 68

Widest divergence: Growth Earnings (C$13.58) versus Asset-Based (C$0.6200). Highest evidence: Growth DCF (80).

Notify me when BRM reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) C$44.4M
Revenue growth (YoY) +44.1%
Net margin 11.2%
Return on equity 38.3%
Free cash flow C$7.3M FY2025
P/E ratio 11.4
More key figures
Operating margin 2.7%
EPS (TTM) C$0.2700
EPS growth (YoY) +450%
Net debt C$1.9M FY2023

Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 73/100

Of which business quality 74 · Market factors (momentum, volatility) 80

Profitability 80
Margins and returns on capital today
Quality Growth 60
Are margins and returns improving?
Cashflow 78
Earnings quality: real cash, not paper profit
Fin. Strength 91
Balance sheet, leverage, solvency risk
Investment 38
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 90
Price trend over the last 3–12 months (market factor)
52W Momentum 100
Distance to the 52-week high (market factor)
Net Issuance 79
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

BioRem Inc., a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds, and hazardous air pollutants.

Full company description

BioRem Inc., a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds, and hazardous air pollutants. The company offers biofilters; biotrickling filters; multi-stage systems; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems. It also sells biofiltration media products under the BIOSORBENS, XLD, BIOPAK, BIOROLL, and BIOBLOK names. The company operates in Canada, the United States, China, and internationally. In addition, its products are used in wastewater and water treatment plants, municipal solid waste and waste to energy, pet food manufacturing, rendering plants, food and beverage, petrochemical, semiconductor, chemical production facilities industries. BioRem Inc. was founded in 1990 and is headquartered in Puslinch, Canada.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

BioRem Inc reported revenue of C$42.4M in FY2025 versus C$24.5M in FY2021, a compound +14.7%/yr. Reported net income was C$4.8M in FY2025, compounding +38.8%/yr from FY2021.

Growth Quality 87/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
C$42.4M
Latest YoY
+13.2%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.6%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+11.7%
Avg. growth/yr (22Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.5%
Revenue +14.7%/yr
FY21 C$24.5M
FY22 C$28.9M
FY23 C$25.2M
FY24 C$37.4M
FY25 C$42.4M
Net income +38.8%/yr
FY21 C$1.3M
FY22 C$1.6M
FY23 C$2.2M
FY24 C$3.0M
FY25 C$4.8M

Watch BRM: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "BioRem Inc Fair Value". https://www.fairvalue-calculator.com/stock/BRM

Peer Group

Pollution & Treatment Controls · 91 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 73 · Top 25%
Fair Value upside +47% · Top 25%
Return on equity (TTM) 38% · Top 25%
Return on assets 14% · Top 25%
Net margin (TTM) 11% · Top 25%
Operating margin (TTM) 3% · Below median
Revenue growth 44% · Top 25%
Debt / equity 0.09× · Lower than median

Valuation Multiples vs Pollution & Treatment Controls median · lower = cheaper

P/E (TTM) 11.4× · Cheaper than median
P/B 2.40× · Pricier than median
P/S (TTM) 0.81× · Cheaper than median
P/FCF 4.9× · Pricier than median
EV/EBITDA 3.7× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 96 · sector 0
FUTURE 100 · sector 14
PAST 100 · sector 10
HEALTH 96 · sector 95
DIVIDEND 0 · sector 37

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pollution & Treatment Controls stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).

Stock Price Fair Value vs Fair Value
Veralto Corporation VLTO $94.21 $69.11 -27%
Zurn Elkay Water Solutions Corporation ZWS $47.63 $24.92 -48%
Canmax Technologies Co 300390 ¥57.02 ¥10.41 -82%
CECO Environmental Corp CECO $83.63 $15.19 -82%
Fujian Longking Co 600388 ¥17.58 ¥15.59 -11%
Munters Group MTRS kr 166.60 kr 16.90 -90%
China Conch Venture Holdings 0586 HK$8.83 HK$14.14 +60%
Mega Union Technology Inc 6944 1,005 TWD 539.58 TWD -46%
MayAir Technology (China) Co 688376 ¥96.57 ¥18.80 -81%
Zhongyuan Environmental Protection Co 000544 ¥7.30 ¥15.46 +112%

Compare BioRem Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is BioRem Inc (BRM) overvalued or undervalued?
As of Jul 15, 2026, our model estimates a fair value of C$5.53 versus a price of C$3.77, about +47% (undervalued).
What is the fair value of BRM?
Our model-based fair value for BioRem Inc is C$5.53 (as of Jul 15, 2026), built from audited fundamentals. The current price is C$3.77.
What is the quality score of BRM?
BioRem Inc has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of BioRem Inc (BRM)?
BioRem Inc reported trailing-twelve-month revenue of about C$44.4M (latest available figure, as of Jul 15, 2026).
What is the net profit margin of BRM?
The net profit margin of BioRem Inc is about 11.2%, meaning it keeps roughly 11.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track BioRem Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.